Zivo Bioscience Inc Financials
This page shows Zivo Bioscience Inc (ZIVO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ZIVO still operates as a financing-dependent development business, where capital raises rather than early revenue fund research and cash use.
FY2024's revenue jump to$157K did not change the operating model because R&D spending still dwarfed sales and operating cash burn remained-$4.3M . Cash burn improved from-$7.1M in FY2022, but a 0.8x current ratio shows liquidity still trails short-term obligations.
The balance sheet became less impaired in FY2024 because financing rebuilt assets to
Early commercial traction is real but economically small: revenue reached
Financial Health Signals
We are recalculating Zivo Bioscience Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Zivo Bioscience Inc passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Key Financial Metrics
Earnings & Revenue
Zivo Bioscience Inc generated $157K in revenue in fiscal year 2024. This represents an increase of 468.6% from the prior year.
Zivo Bioscience Inc earned $-4.23 per diluted share (EPS) in fiscal year 2024. This represents an increase of 8.0% from the prior year.
Cash & Balance Sheet
Zivo Bioscience Inc held $1.5M in cash against $0 in long-term debt as of fiscal year 2024.
Zivo Bioscience Inc had 4M shares outstanding in fiscal year 2024. This represents an increase of 52.0% from the prior year.
Margins & Returns
Zivo Bioscience Inc's gross margin was 31.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 10.8 percentage points from the prior year.
Capital Allocation
Zivo Bioscience Inc invested $3.1M in research and development in fiscal year 2024. This represents an increase of 127.7% from the prior year.
ZIVO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66K+22.9% | $53K | $0 | N/A | $32K | $0-100.0% | $36K | N/A |
| Cost of Revenue | $44K+25.0% | $35K | $0 | N/A | $22K | $0-100.0% | $23K | N/A |
| Gross Profit | $21K+18.8% | $18K | $0 | N/A | $9K | $0-100.0% | $13K | N/A |
| R&D Expenses | $203K-57.6% | $480K-82.7% | $2.8M | N/A | $326K-85.5% | $2.3M+620.1% | $313K | N/A |
| SG&A Expenses | $836K-28.6% | $1.2M-18.6% | $1.4M | N/A | $1.9M | N/A | $976K | N/A |
| Operating Income | -$1.0M+37.6% | -$1.6M+61.2% | -$4.2M | N/A | -$2.3M | N/A | -$1.3M | N/A |
| Interest Expense | $13K+76.1% | $7K+206.7% | $2K | N/A | $9K+26.5% | $7K+155.6% | $3K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Net Income | -$1.0M+37.0% | -$1.6M+61.1% | -$4.2M | N/A | -$2.3M | N/A | -$1.3M | N/A |
| EPS (Diluted) | $-0.27+37.2% | $-0.43+61.6% | $-1.12 | N/A | $-0.67+75.9% | $-2.78-491.5% | $-0.47 | N/A |
ZIVO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $559K-20.5% | $703K-47.2% | $1.3M-19.0% | $1.6M+231.6% | $496K-13.9% | $576K-29.5% | $816K+46.9% | $556K |
| Current Assets | $281K-31.3% | $410K-59.9% | $1.0M-37.5% | $1.6M+274.6% | $437K-11.8% | $495K-30.3% | $711K+67.1% | $425K |
| Cash & Equivalents | $57K+482.5% | $10K-98.1% | $517K-66.5% | $1.5M+867.6% | $159K+6364.0% | $2K-98.2% | $139K-49.5% | $274K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0-100.0% | $34K | $0-100.0% | $2K-92.0% | $28K | $0-100.0% | $4K0.0% | $4K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.8M+18.6% | $3.2M+10.0% | $2.9M+36.6% | $2.2M-16.3% | $2.6M-10.2% | $2.9M-6.9% | $3.1M+11.7% | $2.8M |
| Current Liabilities | $3.6M+22.1% | $3.0M+13.3% | $2.6M+28.0% | $2.0M-20.8% | $2.6M-10.2% | $2.9M-6.9% | $3.1M+11.7% | $2.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.3M-29.4% | -$2.5M-57.1% | -$1.6M-214.1% | -$515K+75.3% | -$2.1M+9.3% | -$2.3M-1.2% | -$2.3M-2.9% | -$2.2M |
| Retained Earnings | -$143.9M-0.7% | -$142.8M-1.2% | -$141.2M-3.1% | -$137.0M-1.2% | -$135.4M-1.7% | -$133.1M-6.6% | -$124.9M-1.0% | -$123.6M |
ZIVO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$267K+44.0% | -$476K+66.7% | -$1.4M-57.9% | -$906K+16.5% | -$1.1M-74.0% | -$624K+63.3% | -$1.7M-137.4% | -$716K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $314K+1114.2% | -$31K-107.6% | $405K-82.3% | $2.3M+84.3% | $1.2M+154.8% | $487K-68.8% | $1.6M+416.1% | -$495K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ZIVO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4%-1.1pp | 33.6% | N/A | N/A | 30.0% | N/A | 35.0% | N/A |
| Operating Margin | -1551.8%+1506.0pp | -3057.8% | N/A | N/A | -7174.7% | N/A | -3571.8% | N/A |
| Net Margin | -1574.2%+1497.4pp | -3071.6% | N/A | N/A | -7201.9% | N/A | -3579.2% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -184.7%+48.6pp | -233.2%+83.1pp | -316.3% | N/A | -457.8% | N/A | -156.6% | N/A |
| Current Ratio | 0.08-0.1 | 0.14-0.3 | 0.39-0.4 | 0.80+0.6 | 0.170.0 | 0.17-0.1 | 0.23+0.1 | 0.15 |
| Debt-to-Equity | -1.17+0.1 | -1.28+0.5 | -1.82+2.4 | -4.19-3.0 | -1.24+0.0 | -1.25+0.1 | -1.36-0.1 | -1.25 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$515K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.80), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Zivo Bioscience Inc's annual revenue?
Zivo Bioscience Inc (ZIVO) reported $157K in total revenue for fiscal year 2024. This represents a 468.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Zivo Bioscience Inc's revenue growing?
Zivo Bioscience Inc (ZIVO) revenue grew by 468.6% year-over-year, from $28K to $157K in fiscal year 2024.
What is Zivo Bioscience Inc's gross margin?
Zivo Bioscience Inc (ZIVO) had a gross margin of 31.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Zivo Bioscience Inc's operating cash flow?
Zivo Bioscience Inc (ZIVO) generated -$4.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Zivo Bioscience Inc's total assets?
Zivo Bioscience Inc (ZIVO) had $1.6M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Zivo Bioscience Inc spend on research and development?
Zivo Bioscience Inc (ZIVO) invested $3.1M in research and development during fiscal year 2024.
What is Zivo Bioscience Inc's current ratio?
Zivo Bioscience Inc (ZIVO) had a current ratio of 0.80 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Zivo Bioscience Inc's debt-to-equity ratio?
Zivo Bioscience Inc (ZIVO) had a debt-to-equity ratio of -4.19 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Zivo Bioscience Inc's cash runway?
Based on fiscal year 2024 data, Zivo Bioscience Inc (ZIVO) had $1.5M in cash against an annual operating cash burn of $4.3M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Zivo Bioscience Inc's debt-to-equity ratio negative or unusual?
Zivo Bioscience Inc (ZIVO) has negative shareholder equity of -$515K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Zivo Bioscience Inc's Piotroski F-Score?
Zivo Bioscience Inc (ZIVO) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.